In England ... a study identifying the cost effectiveness of using Canagliflozin when added to Standard of Care to treat dkd/ckd...
"Canagliflozin was associated with sizable gains in life-years and quality-adjusted life-year (QALYs) over 10 years, with gains increasing with simulation duration. Cost offsets associated with reductions in cardiovascular and renal complications were sufficient to achieve overall net cost savings
The conclusion.... "Model-based extrapolation of the renal and cardiovascular benefits demonstrated in the CREDENCE trial to 10 years suggests that canagliflozin, used as adjunct to SoC with maximal tolerated doses of a RAAS inhibitor, can substantially reduce rates of renal and cardiovascular outcomes, and increase longevity and QALYs versus SoC alone in this high unmet need population in England, while managing to reduce total costs in the process.
to put it succinctly ...the better your model is at identifying future declined in kidney function the better to contain the costs associated...
In Italy ...I have read articles where govt medical organisations have established predictive CKD models which include data such as ethnicity ,regions age etc...these published articles go back to Jan 20 and earlier before CV19 hit....after CV19 the results were significant in showing a high death rate among those with T2D and CKD .. the cost has been enormous... I believe this has reinforced the Gov intention to tackle this problem ...hence ...imo...the early approval of PD... Imo... PD will become part of the Gov's model to identify potential CKD...I believe this model will be followed closely by the medical community and Gov's around the globe...
So...as far as the SP ...Dr RL believe we are undervalued by along way.... also others have pointed out that we have had some significant anns that just may have been under appreciated ... glta
PIQ Price at posting:
74.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)